AIM ImmunoTech (AIM.US) Price Target 2026/2027: 1700% Upside – Rating and Stock Analysis
AIM ImmunoTech Price Target 2026: Analysts See 1,702% Upside
The average price target for AIM ImmunoTech is $4.25. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 1,701.61% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.Is AIM ImmunoTech overvalued or undervalued?
AIM ImmunoTech is currently undervalued with a gap of 1701.6% relative to the price target.
The current price is $0.24, which places AIM ImmunoTech in the undervalued category. The stock is considered undervalued when the price is below $3.83, and overvalued when the price exceeds $4.68.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For AIM ImmunoTech, the fair value range lies between $3.83 and $4.68.
Analyst Ratings for AIM ImmunoTech stock in 2026: Strong Buy
2 analysts cover AIM ImmunoTech. There is broad agreement on a positive view — 100% recommend buying. The average price target is $4.25, which gives an upside of 1701.6% from the current price.
About AIM ImmunoTech – Bioteknologi
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida. Read more about the companyKey Figures for AIM ImmunoTech
What kind of stock is AIM ImmunoTech?
AIM ImmunoTech is classified as a speculative stock.
Score Overview for AIM ImmunoTech
📈 Valuation
The P/S ratio is 72.4 (high — the market pays a premium for the revenue). The P/B ratio is 1.0, below book value, which can point to a value opportunity. The PEG ratio is 0.71 — below 1.0 suggests the stock is cheap relative to its growth rate.
🏦 Financial Health
The Piotroski score is 4 out of 9 — average financial health. Altman Z2 is -117.09 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 1,000.0% — high debt, which raises the risk.
🚀 Momentum & Short Interest
Short interest is 2.28%.
AIM ImmunoTech Short Selling 2026: 2.3% Sold Short
Data is updated daily based on official filings with the SEC.
When Does AIM ImmunoTech Report Earnings?
The next earnings date for AIM ImmunoTech is not yet available. Check the company's investor calendar for more information.Technical Analysis of AIM ImmunoTech 2026 – Signal: Strong Sell
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated September 2, 2026.
Trend Analysis of AIM ImmunoTech Inc
AIM ImmunoTech Inc is in a short-term downtrend. The price of $0.24 is 6.3% below the 20-day average ($0.25). Medium term, the picture is negative: the price is 11.9% below the 50-day average ($0.27). Long term, the stock is 68.0% below the 200-day average ($0.74), which signals a long-term downtrend.
Death Cross: The 50-day average (0.27) is below the 200-day average (0.74), which is a classic bearish signal for AIM ImmunoTech Inc.
Is AIM ImmunoTech Inc overbought or oversold?
AIM ImmunoTech Inc has an RSI of 43.2. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold. In the current downtrend, be careful about reading this as a buying opportunity.
MACD Analysis for AIM ImmunoTech Inc
Daily MACD: MACD is negative (-0.009), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-0.010) by 0.001, which suggests the negative momentum is fading – a potential trend reversal could be ahead.
Weekly MACD: MACD5 is negative (-0.353), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-0.462) by 0.109, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.
Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.
Risk Profile for AIM ImmunoTech Inc
AIM ImmunoTech Inc has an annual standard deviation of 203.7%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.
Overall Technical Conclusion for AIM ImmunoTech Inc
Trend: Negative. The price trades below SMA50 and SMA200.
MACD trend (zero line): Daily bearish (-0.009). Weekly bearish (-0.353).
MACD momentum (signal): Daily rising. Weekly rising.
RSI: 43.2 – neutral.
Technical signal: Strong Sell
The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.